PharmacyCodes



Oxaloplatino [Spanish] en es it fr

Categorie

Oxaloplatino [Spanish] Les marques, Oxaloplatino [Spanish] Analogs

Oxaloplatino [Spanish] Les marques melange

  • No information avaliable

    • Oxaloplatino [Spanish] Formule chimique

    C8H12N2O4Pt

    Oxaloplatino [Spanish] RX lien

    http://www.rxlist.com/cgi/generic/eloxatin.htm

    Oxaloplatino [Spanish] FDA fiche

    Oxaloplatino_[Spanish] FDA

    Oxaloplatino [Spanish] msds (fiche de securite des materiaux)

    Oxaloplatino_[Spanish] MSDS

    Oxaloplatino [Spanish] Synthese de reference

    Aucune information disponible

    Oxaloplatino [Spanish] Poids moleculaire

    395.27 g/mol

    Oxaloplatino [Spanish] Point de fusion

    No information avaliable

    Oxaloplatino [Spanish] H2O Solubilite

    Aucune information disponible

    Oxaloplatino [Spanish] Etat

    Solid

    Oxaloplatino [Spanish] LogP

    No information avaliable

    Oxaloplatino [Spanish] Formes pharmaceutiques

    Aucune information disponible

    Oxaloplatino [Spanish] Indication

    Pour le traitement des tumeurs malignes du côlon, du rectum, et de l'ovaire

    Oxaloplatino [Spanish] Pharmacologie

    L'oxaliplatine inhibe sélectivement la synthèse de l'acide désoxyribonucléique (ADN). Le contenu guanine et la cytosine est corrélée avec le degré d'oxaliplatine induit une réticulation. A des concentrations élevées de la drogue, de l'ARN cellulaire et la synthèse des protéines sont également supprimées.

    Oxaloplatino [Spanish] Absorption

    Aucune information disponible

    Oxaloplatino [Spanish] Toxicite

    Aucune information disponible

    Oxaloplatino [Spanish] Information pour les patients

    Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

    Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

    Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

    Oxaloplatino [Spanish] Organismes affectes

    Les humains et autres mammifères